Efficacy of tyrosine kinase inhibitors (TKI) after combination ipilimumab plus nivolumab (I/N) in metastatic clear cell renal cell carcinoma (ccmRCC) patients: Results from the Canadian Kidney Cancer Information System (CKCis).
Austin Kalirai(University of Alberta), Naveen S. Basappa, Aaron R. Hansen(Princess Margaret Cancer Centre), Rodney H. Breau(University of Ottawa), Isaiah Joy(University of Alberta), Frédéric Pouliot(Université Laval), Myuran Thana(Queen Elizabeth II Health Sciences Centre), Georg A. Bjarnason(Sunnybrook Health Science Centre), Sunita Ghosh(Tata Memorial Hospital), Lori Wood(Dalhousie University), Vincent Castonguay(Centre hospitalier universitaire de Québec), Christian Kollmannsberger(BC Cancer Agency), Jeffrey Graham(University of Calgary), Daniel Yick Chin Heng(University of Calgary), Anil Kapoor(People’s University)
Cited by 0
Related Papers
European Consensus Conference on Diagnosis and Treatment of Germ Cell Cancer: A Report of the Second Meeting of the European Germ Cell Cancer Consensus group (EGCCCG): Part I
|European Urology|2008|617
Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer
|Cancer Discovery|2018|520
Recurrent Uncomplicated Urinary Tract Infections in Women: AUA/CUA/SUFU Guideline
|The Journal of Urology|2019|482
Exosomes Induce Fibroblast Differentiation into Cancer-Associated Fibroblasts through TGFβ Signaling
|Molecular Cancer Research|2018|322
Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline PART I
|The Journal of Urology|2020|268